The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA flu vaccine candidate after holding a high-priority meeting with the company. Last week, the FDA said it refused to file Moderna’s application over regulatory issues. The company maintained that the refusal had nothing to do with…
